A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing

Gene Therapy

Volumn 13, Issue 17, 2006, Pages 1309-1312

  Willmon, C L ^a   Krabbenhoft, E ^a   Black, M E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Fusion gene; Ganciclovir; Guanylate kinase; Thymidine kinase

Indexed keywords

GANCICLOVIR; GUANYLATE KINASE; THYMIDINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; BYSTANDER EFFECT; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; ENZYME ACTIVITY; GENE THERAPY; GENETIC TRANSFECTION; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE THERAPY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; ELECTROPORATION; GANCICLOVIR; GENE THERAPY; GENETIC ENGINEERING; GLIOMA; GUANYLATE KINASE; HERPESVIRUS 1, HUMAN; NEOPLASMS; PRODRUGS; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE;

SIMPLEXVIRUS;

EID: 33747598700     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302794     Document Type: Article

References (23)

1. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004 - an overview. J Gene Med 2004; 6: 597-602.
2. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
3. Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J et al. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)-guanine: A selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983; 80: 4139-4143.
4. Reardon JE. Herpes simplex virus type 1 and DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogs. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989; 264: 19039-19044.
5. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
6. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
7. Kim YG, Bi W, Feliciano ES, Drake RR, Stambrook PJ. Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene. Cancer Gene Ther 2000; 7: 240-246.
8. Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytotoxcity by hydroxyurea. Cancer Res 2000; 60: 1631-1636.
9. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
10. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996; 93: 3525-3529.
11. Kokoris MS, Sabo P, Adman ET, Black ME. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Therapy 1999; 6: 1415-1426.
12. Fridland A, Connelly MC, Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmcol 1990; 37: 665-670.
13. Johansson M, Amiri M, Karlsson A. Phosphorylation of 9-β-Darabinofuranosylguanine monophosphate by Drosophila melanogaster guanylate kinase. Biochem Pharmacol 2005; 70: 987-992.
14. Ostermann N, Lavie A, Padiyar S, Brundiers R, Veit T, Reinstein J et al. Potentiating AZT activation: Structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 2000; 304: 43-53.
15. Boehme RE. Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-propoxymethyl) guanine monophosphate by guanylate kinase isozymes. J Biol Chem 1984; 258: 12346-12349.
16. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980; 255: 7204-7207.
17. Agarwal KC, Miech RP, Parks Jr RE. Guanylate kinases from human erythrocytes, hog brain, and rat liver. Methods Enzymol 1978; 51: 483-490.
18. Gaidarov IO, Suslov ON, Abdulaev NG. Enzymes of the cyclic GMP metabolism in bovine retina. I. Cloning and expression of the gene for guanylate kinase. FEBS Lett 1993; 335: 81-84.
19. Brady WA, Kokoris MS, Fitzgibbon M, Black ME. Cloning, characterization, and modeling of mouse and human guanylate kinases. J Biol Chem 1996; 271: 16734-16740.
20. Stolworthy TS, Krabbenhoft E, Black ME. A novel Escherichia coli strain allows functional analysis of guanylate kinase drug resistance and sensitivity. Anal Biochem 2003; 322: 40-47.
21. Kokoris MS, Sabo P, Black ME. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res 2000; 20: 959-964.
22. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
23. Akyürek LM, Nallamshetty S, Aoki K, San H, Yang Z-H, Nabel GJ et al. Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation. Mol Ther 2001; 3: 779-786.